ECRON-ACUNOVA
4.12.2015 10:24:06 CET | Business Wire | Press release
Anders Malm, Managing Director of Ecron Acunova and responsible for operations in Europe and North America is pleased to announce that Erik Carp has joined Ecron Acunova as Leader Nordic Region.
Erik Carp joined Ecron Acunova in November with responsibility for the Nordic Region. He will bring much operational experience from local and multinational clinical trials within different therapeutic areas. With a Master in pharmacy from Copenhagen University and a Bachelor in business administration from Copenhagen Business School, Erik Carp brings about 25 years of international clinical operations and business experience from pharmaceutical and biotech companies to Ecron Acunova.
Ecron Acunova (www.ecronacunova.com ) is an expert CRO with over 25 years of track record covering 19 European countries, 9 Asian countries and the United States and Canada. It offers full service clinical research including clinical operations, data management, biostatistics, pharmacovigilance, medical writing, PK/PD services and central laboratory services to pharma, biotech, medical device, nutrition and diagnostic companies. Ecron Acunova operates each region as a priority market with European HQ in Frankfurt, Asian HQ in Singapore, and US HQ in Princeton. With a team of over 350 professionals including about 70 MDs and PhDs, Ecron Acunova is reputed to accelerate pharma time‐to‐market cost effectively.
Speaking on the appointment, Anders Malm, CEO Ecron Acunova Europe, said, “Mr. Carp brings extensive experience in clinical research and he has worked with several CROs over the years as a sponsor. With his experience, Erik Carp can contribute to ensuring that Ecron Acunova’s services continue to meet the specific needs of each our sponsors in terms of quality, timing and budgets. We will continue to serve existing clients and build close relations with biotech and pharmaceutical companies for global as well as local services”.
On his appointment, Mr. Carp said, “Ecron Acunova is a CRO with vast experience within many therapeutic areas. With a highly trained staff in three continents Ecron Acunova has a knowledge base which is unique for a CRO of our size. The company has a global reach, while at the same time we can take care of clients on a local and personal basis. The right size matters in this industry and Ecron Acunova can adapt to the size of each of the sponsors we serve. In our organization, each employee can contribute to the success of our sponsors, make a real difference every day, be visible, accountable and constantly strengthen and develop existing and new competencies. It is a pleasure and privilege for me to be part of Ecron Acunova”.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151204005233/en/
Contact:
Ecron Acunova Europe HQ
Anders Malm
anders.malm@ecronacunova.com
+49
69 6680 300
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 01:00:00 CEST | Press release
Expanded footprint advances the company’s global strategy in key growth region for healthcare and pharma brands Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Ka
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
